A direct interaction between two Restless Legs Syndrome predisposing genes : MEIS1 and SKOR1 by Catoire, Helene et al.
This article has been published in a revised form in Scientific Reports [DOI:10.1038/s41598-018-30665-
6]. This version is free to view and download for private research and study only. © Scientific Reports.
1Scientific REPoRTS |  (2018) 8:12173  | DOI:10.1038/s41598-018-30665-6
www.nature.com/scientificreports
A direct interaction between 
two Restless Legs Syndrome 
predisposing genes: MEIS1 and 
SKOR1
Helene Catoire1, Faezeh Sarayloo1,2, Karim Mourabit Amari3, Sergio Apuzzo3, 
Alanna Grant1,2, Daniel Rochefort1, Lan Xiong1,4, Jacques Montplaisir5, Christopher J. Earley6, 
Gustavo Turecki7, Patrick A. Dion1,4 & Guy A. Rouleau1,4
Restless Legs syndrome (RLS) is a common sleep disorder for which the genetic contribution remains 
poorly explained. In 2007, the first large scale genome wide association study (GWAS) identified three 
genomic regions associated with RLS. MEIS1, BTBD9 and MAP2K5/SKOR1 are the only known genes 
located within these loci and their association with RLS was subsequently confirmed in a number of 
follow up GWAS. Following this finding, our group reported the MEIS1 risk haplotype to be associated 
with its decreased expression at the mRNA and protein levels. Here we report the effect of the risk 
variants of the three other genes strongly associated with RLS. While these variants had no effect on 
the mRNA levels of the genes harboring them, we find that the homeobox transcription factor MEIS1 
positively regulates the expression of the transcription co-repressor SKOR1. This regulation appears 
mediated through the binding of MEIS1 at two specific sites located in the SKOR1 promoter region 
and is modified by an RLS associated SNP in the promoter region of the gene. Our findings directly link 
MEIS1 and SKOR1, two significantly associated genes with RLS and also prioritize SKOR1 over MAP2K5 
in the RLS associated intergenic region of MAP2K5/SKOR1 found by GWAS.
Restless Legs syndrome (RLS), also known as Willis-Ekbom disease (WED) or Wittmaack-Ekbom syndrome, is a 
common sleep-related sensorimotor disorder characterized by an urge to move the legs to relieve uncomfortable 
sensations. These sensations occur, or worsen, during rest, such as before falling asleep or during the night1. RLS 
is a circadian sensorimotor dysregulation disorder that can lead to severe sleep disturbances and impaired quality 
of life2,3. Epidemiological studies have established that RLS is a common neurological disorder with a prevalence 
of up to 15% in Central Europe and North America4–12.
In 2007, a genome-wide association study (GWAS) conducted using German and French-Canadian RLS cases 
and control individuals identified variants in three genomic regions located on chromosomes 2p, 6p and 15q13. 
One of these loci was in an intronic region of the homeobox gene MEIS1. A second locus was in the BTBD9 
gene, which encodes a BTB (POZ) domain. The third locus was between the MAP2K5 gene, which encodes a 
mitogen-activated protein kinase and the SKOR1 gene, which encodes a transcription factor (in the 2007 study, 
SKOR1 was previously referred to as LBXCOR1)13. During the same year, an independent GWAS studying cases 
and controls from Iceland also identified an association between BTBD9 and periodic limb movements in sleep 
(PLMS), a motor feature strongly associated with RLS14. A third independent GWAS conducted with cases from 
the United States also replicated the association of MEIS1 and BTBD9 with RLS15. Two years later our group 
further confirmed the association between MEIS1 and RLS as we established that the intronic risk haplotype 
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(rs12469063/rs2300478: GG/GG) led to decreased expression of the gene at both the mRNA and protein levels in 
both brain tissues and lymphoblastoid cell lines (LCL) derived from patients16.
The first line of treatment for RLS are dopamine agonists like levodopa, suggesting that reduced dopaminergic 
activity is involved in the pathogenesis17. However, there can be negative side effects to the administration of 
dopaminergic drugs, like augmentation of overall RLS symptoms18. Iron deficiency anemia, end stage renal dis-
ease and multiple pregnancies increase the risk of RLS. The fact that iron supplements relieve symptoms in many 
of these cases strongly implicated iron in disease pathogenesis19. Studies suggest a dysfunction in the transfer of 
iron between the serum and the central nervous system, possibly involving the blood brain barrier20–22.
To extend on these previous reports and explore the pathogenic molecular mechanisms we looked for inter-
actions between the different RLS-associated genes. First, we investigated the effects of the risk variants on the 
mRNA expression levels of the genes harboring them and the other RLS associated genes (MEIS1, BTBD9, 
MAP2K5 and SKOR1). The positive interaction between MEIS1 and SKOR1 was further explored using specific 
protein-DNA binding studies and promoter reporter assays.
Results
BTBD9, MAP2K5 and SKOR1 expression in LCL, thalamus and pons samples of RLS patients 
with the corresponding risk variants. Given our previous report highlighting the decreased levels of 
MEIS1 mRNA and protein in LCL and thalamus in RLS cases who carry a MEIS1-risk haplotype16, we examined 
if other RLS GWAS-risk variants13,15,23 might also affect the expression of the genes harboring them. For this 
purpose we used quantitative RT-PCR Taqman assays and biological material (LCL and brain tissues: pons and 
thalamus) to test for variations in the expression levels of these genes in RLS patients with these risk variants, 
similar to our previous report16.
First, we tested the rs3923809 SNP (A as the risk allele) that is located in intron 5 of BTBD9 (Fig. 1A). When 
mRNA expression was measured in LCL no significant variations were seen between individuals with G/G, A/G 
and A/A alleles, though we had access to only four LCL of individuals homozygous for the non-risk allele (G/G). 
Next we measured mRNA levels of two brain regions to further explore the effects of this SNP. On average in the 
pons and thalamus of RLS patients who were heterozygous (A/G) carriers of the risk allele there appeared to be 
an increased level of BTBD9 mRNA, though the distribution of individual samples was too broad to conclude if 
there was a significant difference between individuals carrying either the A/A or A/G alleles. Moreover, the lack of 
access to brains from cases homozygous for the G/G allele prevented us from arriving at a conclusion.
Next we tested the rs3784709 SNP (C as the risk allele) located in the intergenic region between MAP2K5 
and SKOR1. No effect was observed to be driven by this risk allele (which is the common allele) on the mRNA 
expression of either MAP2K5 (Fig. 1B) or SKOR1 (Fig. 1C); unfortunately the number of RLS brain samples from 
cases that were homozygous for the rare allele was limited. Nonetheless, the quantitative RT-PCR Taqman assays 
prepared from LCL suggest the mRNA levels of the two genes were not affected by the presence of the risk allele.
SKOR1 expression is linked to the MEIS1 risk haplotype. After establishing the effect of each risk 
variant on the expression level of the genes harboring them, we looked for links between each of the risk variants 
and the other susceptibility genes. No significant effect on expression was observed between these genes except 
for the case of SKOR1 expression, which varied according to the MEIS1 risk haplotype. Using LCL we observed 
a significantly decreased expression (P = 0.0202) of SKOR1 in RLS cases who were homozygous carriers of the 
MEIS1 risk haplotype (rs12469063/rs2300478: GG/GG) by comparison to individuals who were homozygous 
for the MEIS1 non-risk haplotype (AA/TT). The same SKOR1 expression measures were made using thalamus 
samples obtained from individuals carrying the same MEIS1 haplotypes and these confirmed a similar decrease 
of expression(P = 0.0174). Analysis of the pons samples from the same individuals did not show a significant 
decrease of expression (P = 0.1519) (Fig. 2A). The same profile, i.e. significant change in LCL and thalamus sam-
ples and non-significant trend in pons samples, was observed in our earlier MEIS1 expression study16. We tried 
to confirm if the mRNA decrease translated to a decreased level of SKOR1 protein. However, none of antisera we 
tested (commercially available or produced by us using SKOR1 peptides) were found to be reliable as all were 
prone to produce various patterns of non-specific signals.
Reduced level of MEIS1 is directly associated with reduced SKOR1 level. We previously reported 
the MEIS1 risk haplotype (GG/GG) to be associated with decreased levels of both its mRNA and protein16. Hence, 
we decided to test if silencing MEIS1 would result in a reduction of SKOR1 mRNA. Using an siRNA (small inter-
fering RNA) specifically targeting MEIS1 we reduced the expression of the gene (~70% mRNA decrease) in HeLa 
cells and found a coincident 64% decrease of SKOR1 mRNA level (P < 0.0001) (Fig. 2B). This observation further 
supports the existence of a link between MEIS1 and SKOR1 and suggests that MEIS1 is an upstream activator of 
SKOR1.
MEIS1 binding sites within the promoter of SKOR1. Since MEIS1 is a homeobox gene that encodes 
a DNA binding transcription factor, we hypothesized that it might regulate the expression of SKOR1 by binding 
to its promoter region. A literature search revealed that MEIS1 and members of another family of homeobox 
genes, PBXs (pre-B cell leukemia transcription factors like Pbx1; reviewed by Longobardi et al.24) form in vivo 
heterodimeric DNA binding complexes with each other and their DNA binding is more intense when together 
than when either Meis1 or Pbx1 are alone25,26. We searched for the presence of MEIS1/PBX1 consensus binding 
sites25–27 (Supplementary Fig. 1) across ~20 kb of human genomic sequence encompassing the ATG start codon of 
SKOR1, ~20 kb of sequence downstream of the stop codon, and all of SKOR1 intronic sequences. Keeping in mind 
that MAP2K5 gene is located 12 kb upstream SKOR1 gene, we chose to search for the binding sites of MEIS1 in the 
aforementioned distance of SKOR1 ATG start site. Three potential MEIS1/PBX1 binding sites were found: one at 
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~8.7 kb upstream of the ATG (TGACAGgcAGgT), a second one at ~1.76 kb upstream (TGACAGagTGAg) and a 
third one at ~2.6 kb downstream of the ATG, in intron 2 of the canonical isoform of SKOR1 (GGACAGtaTGAT). 
Our search was focused on the hexameric consensus binding site of MEIS1. Moreover a search for the octameric 
consensus binding site of MEIS1 (TGATTG/TAT), as reported by Penkov et al., did not reveal any such sites 
in upstream regulatory region and the fist intron of SKOR1 gene28. It is also noteworthy that an examination 
of Meis1 ChIP-Seq (Chromatin immunoprecipitation followed by high throughput sequencing) data made in 
the mouse (GEO database #GSM2188919), shows two Meis1 binding sites upstream Skor1 gene (mm8 genome 
assembly) which suggest they are likely real elements involved in the activation of Skor1 (Fig. S5)29,30.
Through the use of pBluescript vectors with either the coding sequence of wild-type and mutated (to serve 
as negative controls) murine forms of the proteins (Meis1 or Pbx1) we prepared purified proteins using TNT 
Figure 1. (A) BTBD9 expression as a function of the genotype of the SNP rs3923809 identified in the GWAS 
(common allele A as the risk allele) in 44 cases of LCL, 26 cases of pons and 28 cases of thalamus. BTBD9 
expression was measured using quantitative RT-PCR Taqman method and did not show any significant 
difference in LCL or brains from RLS patients. (B) MAP2K5 expression as a function of the genotype of the SNP 
rs3784709 identified in the GWAS (common allele C as the risk allele) in 29 cases of LCL, 30 cases of pons and 
25 cases of thalamus. MAP2K5 expression was measured using the quantitative RT-PCR Taqman method and 
did not show any significant difference in LCL or brains from RLS patients. (C) SKOR1 expression as a function 
of the genotype of the same SNP rs3784709 identified in the GWAS (C as the risk allele) in 43 cases of LCL, 
30 cases of pons and 29 cases of thalamus. SKOR1 expression was measured using the quantitative RT-PCR 
Taqman and did not reveal any significant difference in LCL or brains from RLS patients.
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Coupled Reticulocyte Lysate Systems (Promega). The purified proteins were used in electrophoretic mobility 
shift assay (EMSA) experiments testing the three different human MEIS1/PBX1 binding sequences (~8.7 kb and 
~1.76 kb sites upstream to the ATG and the ~2.6 kb site downstream to the ATG) (Fig. 2C). The ~2.6 kb site 
downstream to the ATG (the only binding site conserved in mouse, rat, cow and chimpanzee) did not bind to 
MEIS1 (Fig. 2C) and therefore is unlikely to directly affect the expression of SKOR1. However, we observed strong 
bindings for the two other sites (~8.7 kb and ~1.76 kb upstream to the ATG) (Fig. 2C). Overall, the in vitro EMSA 
indicates that there is a physical interaction between the MEIS1 protein and the promoter of SKOR1 at two differ-
ent positions. In light of the decreased SKOR1 expression that was observed in RLS cases who were homozygous 
carriers of the MEIS1 risk haplotype (Fig. 2A), this interaction between MEIS1 and the SKOR1 promoter region 
strongly suggests a direct link between those two RLS risk genes, with MEIS1 being a regulator of SKOR1.
Case control association study of an additional SNP near the ~8.7 kb MEIS1 binding site. An 
association study including unrelated and consecutively recruited RLS patients in Montreal, Canada (n = 401) 
and controls (n = 588) of European ancestry, recruited as previously described31. The average age at enrollment 
of RLS patients was 52.5 ± 14.9 years, with 38.5% men. Patients were diagnosed based on the international RLS 
study group (IRLSSG) criteria32. The average age at enrollment of the control population was 53.0 ± 16.1 years, 
Figure 2. (A) SKOR1 expression as a function of MEIS1 genotype in 41 cases of LCL, 27 cases of pons and 
27 cases of thalamus. SKOR1 expression measured using the quantitative RT-PCR Taqman method showed a 
significant decrease of expression in LCL and thalamus with the MEIS1 risk haplotype (GG/GG). (B) SKOR1 
expression in human HeLa cells after silencing MEIS1 gene by siRNA (70% decreased expression). (C) 
Electrophoretic mobility shift assay showing the binding of MEIS1 and PBX1 on the positive control DNA 
portion only when together and on the three different DNA portions containing the three potential binding 
sites. (see Supplemental data, Fig. S4 for original image) (D) Luciferase assay. The results are calculated as a 
ratio of luciferase expression (ratio firefly / Renilla luciferase expression) and are presented as the percentage 
of samples with knocked-down MEIS1 expression (treated with siRNA directed against MEIS1) in comparison 
to samples with wild-type endogenous MEIS1 expression (negative control siRNA). As shown in the figure, P1 
segment with the C allele and P2 segment (no polymorphisms present) show decreased luciferase expression 
as a result of reduced MEIS1 expression using siRNA. *p < 0.05, **p < 0.01 and ***p < 0.001 compared as 
indicated.
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with 38.2% men. There is no significant difference in sex and age between the cases and controls. The frequency 
of the risk allele (C) of rs4776976 is 0.848 in RLS cases and 0.776 in controls, respectively; and the genotype 
distribution fits with the Hardy-Weinberg equilibrium. The p value for the association test of the C risk allele is 
0.0001267. The RLS risk allele (C) of rs4776976 is the most common allele in the European population (0.8) while 
the non-risk T allele of rs4776976 is the less frequent (0.2); as observed on gnom Aggregation Database33.
We first tested if the rs4776976 SNP might influence SKOR1 expression and so our mRNA expression data was 
revisited using the two possible genotypes (C and T) (Supplementary Fig. 2). No significant effect of the risk allele 
was observed on SKOR1 expression in the LCL, pons or thalamus patient samples.
Contribution of MEIS1 binding sites upstream SKOR1. To test how MEIS1 influences the expression 
of SKOR1 and measure to what extent the C or T alleles at rs4776976 might affect the binding of MEIS1 at the 
~8.7 kb site we used dual-luciferase assay experiments to obtain quantitative measures of expression. The ~20 kb 
of SKOR1 promoter region is too large to be cloned as a single fragment upstream of a firefly luciferase reporter 
(PGL3, Promega) and so it was divided into two separate fragments (P1 contained the ~8.7 kb binding site and 
nearby rs4776976 SNP (C or T) and P2 the ~1.76 kb (Supplementary Fig. 3). These two PGL3 vectors and an 
empty PGL3 vector were separately co-transfected into HeLa cells alongside a vector expressing a Renilla lucif-
erase. To quantify the contribution of MEIS1 on SKOR1 expression, the different pGL3 luciferase vectors were 
independently co-transfected in HeLa cells with either siRNA targeting MEIS1 or control low GC duplex siRNA 
to mimic the decreased expression of MEIS1 known to be associated with its risk haplotype. For each PGL3 lucif-
erase vector a percentage was calculated between cells co-transfected with the MEIS1 siRNA and the negative 
siRNA control (the luciferase values used to calculate these ratios were normalized from the firefly and Renilla 
signals) (Fig. 2D).
In the presence of MEIS1 siRNA, a significant decrease (∼40%) of luciferase expression occurred when driven 
by the P1 fragment with the rs4776976 C risk allele (P < 0.001), by comparison the P1 fragment with the T 
rs4776976 allele does not affect the luciferase expression. This suggests that the presence of C allele that represents 
the common RLS risk allele results in binding of MEIS1/PBX1 to the P1 segment of SKOR1 promoter region. 
When the luciferase expression was driven by the P2 fragment a significant decrease (P < 0.01) also occurred, 
thus confirming this potential MEIS1/PBX1 binding site was recognized by MEIS1 in our assay. This experiment 
demonstrates that MEIS1 physically acts as a direct activator of SKOR1 and shows that the rs4776976 SNP plays 
an important role for the binding of MEIS1 on SKOR1 promoter, where the presence of C allele results in SKOR1 
gene being regulated by MEIS1.
Discussion
It is important to understand if genes identified using GWA studies interact with each other, how they exert 
their biological effects and which are the variants driving the association34. We previously showed that the RLS 
associated risk haplotype within the MEIS1 non-coding regions is associated with a decreased expression of this 
gene in the RLS patient LCL and thalamus samples16. Here we show that one of the consequences of this reduced 
expression is reduced expression of SKOR1. No other risk variants in the other GWAS RLS susceptibility loci show 
any significant correlation with the expression levels of the genes harboring them. Considering that MEIS1, a 
homeobox gene, is a transcription factor with precise temporal and spatial gene expression during development35, 
this link could be a result of transcriptional regulatory function of MEIS1 on SKOR1, which we confirmed using 
EMSA and a luciferase reporter assay.
We also report a new SNP in the ∼8.7 kb upstream region of the SKOR1 ATG start site that is a regulatory 
SNP (rSNP), as it affects the MEIS1 regulation of SKOR1. We found that when the risk allele is present, reduced 
MEIS1 expression leads to reduced SKOR1 expression, whereas with the non-risk allele there are no changes in 
the expression of SKOR1 (null allele). These data suggest that a reduced level SKOR1 expression might be rele-
vant to the development of a subset of RLS cases, and therefore it will be important to understand what are the 
downstream effects of reduced SKOR1 expression. Finally, these data also suggest that the variant driving the 
association with RLS in the SKOR1 locus is rs4776976.
Our findings directly linking MEIS1 and SKOR1 strongly suggest that for the GWAS locus MAP2K5/SKOR1, 
the gene associated with RLS is SKOR1 and not MAP2K5. SKOR1 or SKI family transcriptional corepressor 1 
is highly expressed in the central nervous system of human and mouse. In human, it appears to become more 
restricted to Purkinje cells of the cerebellum during adulthood36. The murine Skor1 interacts with a homeodo-
main transcription factor (Lbx1) to cooperatively repress transcription selectively in dorsal horn interneurons of 
the developing spinal cord37. It also appears to be a transcriptional corepressor which among others can regulate 
cell fate determination in murine dorsal spinal cord37. The necessity of Lbx1/Skor1 for generation of GABAergic 
phenotypes in dorsal horn interneurons of spinal cord potentially implicate them in the modulation of pain and 
sensory input processing of RLS38–40.
In a post GWAS era, one of the initial strategies to progress from the tag SNPs to the mechanisms underlying 
the disorders is to use expression studies on human patient cells harboring risk variants. In this study, establishing 
a link between the risk haplotype within the MEIS1 genomic region as well the MEIS1 protein as a transcrip-
tion factor with the SKOR1 promoter sequences opens an avenue for future studies on the regulatory function 
of MEIS1 in the RLS pathogenesis mechanism as well as emphasizing the importance of the other candidate 
gene, SKOR1. Keeping in mind SKOR1’s expression pattern, as well as its proposed function as a developmental 
co-repressor, we can proceed to the subsequent research into RLS molecular mechanisms with a greater focus on 
the regulatory function of MEIS1 and SKOR1, two highly significantly associated genes with RLS.
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Material and Methods
DNA samples. Brain tissue specimens (thalamus and upper pons) were obtained from autopsy brain tissues 
of 31 individuals with an RLS diagnosis from the Harvard Brain Tissue Resource Center. Final diagnosis was 
made by an RLS expert based on available questionnaires and medical records, but blinded to the genotype infor-
mation; these samples were previously used in our earlier RLS studies16,22.
LCL culture. Selected LCL from RLS patients previously established by transformation with EB virus using 
standard protocols were grown at 37 °C and 5% CO2 in RPMI 1640 medium (Invitrogen) supplemented with 15% 
(v/v) heat-inactivated fetal calf serum (Sigma-Aldrich), 0.29 mg/ml of l-glutamine, 100 U/ml of penicillin and 
100 µg/ml of streptomycin (Invitrogen). Healthy cells were harvested at an approximate density of 1 × 106 cells/ml.
RNA expression assays. Total RNA was extracted from 0.2 g of frozen brain tissue using the RNeasy® 
Lipid Tissue kit (Qiagen) or from 5 million lymphoblastoid cells using the RNeasy® kit (Qiagen). Single-stranded 
cDNA synthesis was performed from 1 µg of total RNA using a mix of oligo-dT and random primers and the 
Quantitect® Reverse Transcription kit (Qiagen) or the SuperScript® VILO™ cDNA Synthesis Kit (Invitrogen). 
Quantitative RT-PCR was performed using the TaqMan method (Applied Biosystems) with probes and primers 
designed by Applied Biosystems recognizing BTBD9 (Hs00537653_m1) and MAP2K5 (Hs00177134_m1) and a 
custom probe designed at the junction of two exons of SKOR1 (AJ1RULU). PCR conditions were as follows: 50 °C 
for 2 min, 95 °C for 10 min, followed by 40 cycles at 95 °C for 15 sec (denaturation) and 60 °C for 1 min (annealing 
and extension). Fluorescent signals were captured using the ABI PRISM® 7900HT Sequence Detection System 
(Applied Biosystems). The level of expression was determined by converting the threshold cycle (Ct) values using 
the 2−∆∆Ct method. Expression levels were normalized using the human 18 S ribosomal RNA (rRNA) gene with 
commercial primer-probe mix (Applied Biosystems) or the human polR2A control (Hs00172187_m1). All exper-
iments were run in triplicate. Independent cDNA synthesis was carried out twice. ANOVA test and post-hoc 
Tukey’s test was used for statistics of all tissues with three genotypes. t-test was used for statistics of BTBD9 expres-
sion in thalamus and pons with only two genotypes.
siRNA assays. The artificial 70% decreased expression of MEIS1 was realised by transfection of 100pmol 
of the MEIS1 siRNA (Qiagen, Hs_MEIS1_10, #SI04321331) for 48 hours in HeLa cells using the jetPRIME® 
(Polyplus) transfection reagent. The negative control cells were transfected with low GC duplex control siRNA. 
Total RNA was then extracted following a classical protocol using TRIzol® (Invitrogen) and SKOR1 expression 
measured as described above. This experiment was run in triplicate and t-test was used for statistics.
Electrophoretic mobility shift assay. The binding of MEIS1 and Pbx1 on SKOR1 promoter has been 
tested at the three potential sites with an electrophoretic mobility shift assay. Using vectors (PCS2) designed 
to express either wild-type or mutated (N51S for both, since 51 is a crucial position of homeobox domains) 
MEIS1 or Pbx1 (provided by Dr. Featherstone), purified proteins were prepared using in vitro transcription/
translation (IVTT) (TNT Coupled Reticulocyte Lysate Systems part #TB126, Promega). On the other hand, DNA 
probes were prepared by annealing of the complementary following oligonucleotides (SKOR1_+2.6_top: tca aac 
ttg ggc cgg aca gta tga tta att aca gtt taa tt; SKOR1_+2.6_bottom: taa tta aac tgt aat taa tca tac tgt ccg gcc caa gtt 
tg; SKOR1_−1,76_top: tgc act cca gcc tgg gtg aca gag tga gtg aga ttc cat ttc; SKOR1_−1,76_bottom: tga aat gga 
atc tca ctc act ctg tca ccc agg ctg gag tgc; SKOR1_-8,7_top: tgg ccc cag ttc aca atg aca ggc agg tgc ctc ctc tgc ttc; 
SKOR1_−8,7_bottom: tga agc aga gga ggc acc tgc ctg tca ttg tga act ggg gcc; Consensus_top: tac tgc tgc gat gat tga 
cag ccg cct cg; Consensus_bottom: tcg agg cgg ctg tca atc atc gca gca gt) in SSC buffer, marked with dATP 32 P 
using the Large (Klenow) Fragment DNA polymerase (Invitrogen) and purified using Microspin™ G50 columns 
(GE Healthcare). The resulting proteins and DNA probes were incubated for 20 minutes at room temperature with 
Poly DiDc 0,1 U/μL (Novagen) and BindBuffer (Glycerol 24%, KCl 200 mM, TRIS pH 7,5 20 mM, MgCl2 6 mM, 
EDTA pH 8,5 0,2 mM, Dithiothreitol 2 mM) for DNA-protein interaction and the mix was then loaded on a 30% 
acrylamide:bisacrylamide gel which has been pre-run at 100 V for 30 minutes. Electrophoresis is performed at 
125 Volts for 45 minutes. The gel is then dried under vacuum at 80 °C for 45 minutes and autoradiography is per-
formed with a time of exposure of 48 hours.
Constructs for luciferase assay. To perform luciferase assays, we inserted genomic fragments from the 
SKOR1 promoter into PGL3 vectors expressing the firefly luciferase gene. The ~20 kb of SKOR1 promoter region is 
too long for its cloning as one piece so we cut this region into two segments; each one containing one of the poten-
tial MEIS1/Pbx1 binding site. P1 is the most upstream segment from the ATG and contains the ~8.7 kb MEIS1/
Pbx1 binding site. This fragment of 5,287 bp was amplified with Phusion DNA polymerase (New England Biolabs) 
from BAC clone RP11-207J8 and using the following primers: fwd_5′-gag ctc tta cgc gtg cta gcc cgg gct cga gag 
ggt gcc tgt ggt gtg gga cgg tag g-3′, rev_5′-ctg act aat tga gat gca gat cgc aga tct taa att gtc ttg acc cct tgc tgg ttt tt-3′. 
This P1 fragment was produced with 2 alternatives (P1 form with a risk allele C at the position of rs4776976 SNP 
and a P1 form with a T at the same position) and using QuikChange® Site-Directed Mutagenesis (Agilent). The 
resultant PCR amplicons were then cloned into the XhoI site of pGL3-promoter vector (Promega) containing a 
SV40 promoter upstream of the firefly luciferase gene with the sequence and ligation independent cloning (slic) 
method41. P2 is the closest segment to the ATG start codon and contains the ~1.76 kb MEIS1/Pbx1 binding site. 
This fragment of 1,535 bp was amplified from same BAC clone using the following primers: fwd_5′-gct ctt acg 
cgt gct agc ccg ggg tcg acg cca aaa aga ggg aag aac c-3′, rev_5′-cta att gag atg cag atc gca gat ctc gag acc agg tcc cac 
ttg act tg-3′. The cloning of P2 fragment was identical to P1. Resultant clones were screened for the presence of 
the insert and the sequence of positive clones was verified using Sanger sequencing (Genome Quebec Innovation 
Centre).
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Case Control association study. Genotyping of rs4776976 (C/T) was done using TaqMan assays 
C__11771023_10, following the manufacturer’s instructions. The genotypes were called using the Applied 
Biosystems 7900 Fast Real-Time Polymerase Chain Reaction (PCR) System and Safety Data Sheet (SDS) software 
(v. 2.2.2). The goodness-of-fit test with one degree of freedom (df) was applied to check for the genotype distri-
bution deviation from the Hardy–Weinberg equilibrium. The χ2 and Student’s t-tests were used to determine dif-
ferences in sex and age, respectively. The association test between the marker rs4776976 and RLS was performed 
using the PLINK program42.
Luciferase assay. At day 1, 100,000 HeLa cells per well were plated in a 24-well plate. At day 2, transfec-
tion was performed with 100 ng or 200 ng of one of the following vector expressing the firefly luciferase (empty 
PGL3-Promoter vector; risk or non-risk variant P1, or P2 in PGL3 vectors), 100 ng of the vector containing 
the Renilla luciferase and 25 pmol of siRNA (MEIS1 or negative control) using the attractene transfection rea-
gent (Qiagen). After 48 hours, cells were rinsed with PBS and lysed with 100 ul of passive lysis buffer from the 
Dual-Luciferase® reporter assay (Promega). Firefly and Renilla luciferase activity was then read using the same 
kit and a Synergy 4 microplate reader (Biotek). ANOVA test was used for statistics. The luciferase expression was 
measured as a ratio between firefly and Renilla expression.
Statistics. All statistical analyses of expression studies were performed using GraphPad Prism 5.0 software 
(GraphPad Software Inc.) by one-way ANOVA followed by post-hoc Tukey’s test for significant results. Student’s 
t test was only used for Fig. 1A, for thalamus and pons samples that we only had samples with two different geno-
types for each and for Fig. 2B, for the comparison of the 2 transfected groups with either negative control siRNA 
or specific MEIS1 siRNA. All functional assay experiments are representations of at least 3 independent experi-
ments expressed as mean ± SEM. Statistical significance was considered with a P value less than 0.05. In the case 
control association study, χ2 and Student’s t-tests were used to determine differences in sex and age, respectively. 
The association test between the marker rs4776976 and RLS was performed using the PLINK program by basic 
allelic chi-square test (1df).
Study approval. Lymphoblastoid cell lines (LCL) were prepared from individuals who signed an informed 
consent form before entering the study; the biobanking of LCL has been reviewed and approved by the insti-
tutional review board of McGill University (project # 2015-164, MP-CUSM-14-051). RLS brain tissues were 
provided by the Harvard Brain Tissue Resource Center, which is supported in part by a Public Health Service 
Grant (R24MH068855), with permission from the RLS Brain Bank Tissue Review Committee through the RLS 
Foundation. Control brain tissues were provided by the Douglas-Bell Canada Brain Bank (Douglas Mental Health 
University Institute, Montreal, Quebec, Canada). In the case control association study of rs4776976 with RLS, all 
participants signed informed consent at enrollment, and the study protocols were approved by the institutional 
ethics review boards. This study was approved by Comité d’éthique de la recherche du Centre hospitalier de l′Uni-
versité de Montréal and McGill University ethics, all methods were performed in accordance with the relevant 
guidelines and regulations of McGill University (REB NEU-14-051).
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